PRESS RELEASE published on 12/10/2025 at 17:45, 7 months 22 days ago Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® Valneva reports positive final phase 2 antibody persistence and safety results for children with its Chikungunya vaccine IXCHIQ®. Twelve-month data supports full dose selection for Phase 3 trial Phase 3 Trial Valneva Vaccine Chikungunya Antibody Persistence
BRIEF published on 12/05/2025 at 18:39, 7 months 27 days ago Valneva Updates Share and Voting Rights as of November 2025 Stock Options Euronext Paris Voting Rights Valneva Double Voting Rights
BRIEF published on 12/05/2025 at 18:39, 7 months 27 days ago VALNEVA: Declaration of Shares and Voting Rights Euronext Paris Voting Rights Ordinary Shares Valneva 2025
PRESS RELEASE published on 12/05/2025 at 18:34, 7 months 27 days ago VALNEVA Declaration of shares and voting rights: November 30, 2025 VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form Euronext Paris Voting Rights Shares Valneva Double Voting Rights
BRIEF published on 12/03/2025 at 11:03, 7 months 30 days ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 7 months 30 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 8 months 28 days ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
PRESS RELEASE published on 11/04/2025 at 07:00, 8 months 28 days ago Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Valneva SE reports positive Phase 1 trial results for VLA1601, its second-generation Zika vaccine candidate, showing improved immune response. Safety and immunogenicity demonstrated in trial Phase 1 Trial Valneva SE Safety Immunogenicity Zika Vaccine
BRIEF published on 10/09/2025 at 16:04, 9 months 23 days ago Bpifrance Crosses Threshold in the Capital of Valneva SE Stock Market Valneva SE Threshold Crossing Bpifrance Deposit Fund
BRIEF published on 10/06/2025 at 07:35, 9 months 27 days ago Valneva Updates on Shares and Voting Rights Voting Rights Shares Euronext Valneva France
Published on 08/01/2026 at 01:20, 1 day 11 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 11 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 11 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 13 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 4 hours 7 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 19 hours 46 minutes ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 1 day 16 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 1 day 17 hours ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 15 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 1 day 17 hours ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 1 day 17 hours ago Covivio Hotels - 2026 Half-year financial report
